Literature DB >> 24220178

[Societal costs of asthma, COPD and respiratory allergy].

Anita W M Suijkerbuijk1, G A Ardine de Wit, Alet H Wijga, Monique J W M Heijmans, Martine Hoogendoorn, Maureen P M H Rutten-van Mölken, Erica E M Maurits, Rudolf T Hoogenveen, Talitha L Feenstra.   

Abstract

OBJECTIVE: To estimate the societal costs of asthma, COPD and respiratory allergy for the year 2007 and future healthcare costs for the period 2007-2032.
DESIGN: Descriptive study.
METHODS: Representative registries were used to estimate the healthcare costs of asthma, COPD and respiratory allergy for the year 2007. A simulation model for asthma and COPD and a demographic projection for respiratory allergy were used to determine future healthcare costs. Production losses due to sick leave and work incapacity were calculated using the friction-cost method.
RESULTS: Total healthcare costs for asthma, COPD and respiratory allergy in 2007 were estimated at 287, 415 and 103 million euros respectively; on average 530, 1400 and 170 euros per patient with asthma, COPD and respiratory allergy. Average costs of sick leave for asthma were on average 1200 euros and for COPD 1900 euros per employee per year. The costs of work incapacity of an employee with COPD were 1200 euros. There is expected to be an increase in the number of patients from 443,000 in 2007 to 567,000 in 2032 for asthma and from 335,000 to 600,000 for COPD. The number of patients with a respiratory allergy are expected to remain approximately stable at 625,000 patients. The healthcare costs for respiratory allergy are expected to rise by 73%, those for asthma to double, and those for COPD to triple.
CONCLUSION: Patients with asthma and COPD have high healthcare costs. Sick leave makes up a large part of the costs of asthma and COPD. In addition, the costs of work incapacity for employees with COPD are high. The number of patients with asthma and COPD will rise in the coming decades, as well as the healthcare costs for these diseases.

Entities:  

Mesh:

Year:  2013        PMID: 24220178

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  5 in total

1.  Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.

Authors:  Aureliano Paolo Finch; Patricia van Velzen; Gerben Ter Riet; Peter J Sterk; Jan M Prins; Judith E Bosmans
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

2.  Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.

Authors:  Job Fm van Boven; Janwillem Wh Kocks; Maarten J Postma
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-19

3.  Assessment of cost-effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD.

Authors:  Charlotte Anraad; Kei-Long Cheung; Mickaël Hiligsmann; Kathryn Coyle; Doug Coyle; Lesley Owen; Robert West; Hein de Vries; Silvia M Evers; Subhash Pokhrel
Journal:  Addiction       Date:  2018-02-11       Impact factor: 6.526

4.  Models for estimating and projecting global, regional and national prevalence and disease burden of asthma: a systematic review.

Authors:  Mohammad Romel Bhuia; Md Atiqul Islam; Bright I Nwaru; Christopher J Weir; Aziz Sheikh
Journal:  J Glob Health       Date:  2020-12-30       Impact factor: 4.413

5.  Is it cost-effective to provide internet-based interventions to complement the current provision of smoking cessation services in the Netherlands? An analysis based on the EQUIPTMOD.

Authors:  Kei-Long Cheung; Ben F M Wijnen; Mickaël Hiligsmann; Kathryn Coyle; Doug Coyle; Subhash Pokhrel; Hein de Vries; Maximilian Präger; Silvia M A A Evers
Journal:  Addiction       Date:  2017-12-15       Impact factor: 6.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.